Pharma BD Deal Intelligence
Roche paid $56.5M for a human-antibody platform in 2007 and the founders left to build a rival that became far more valuable elsewhere.
Full analysis, sources & comparables →Roche head of global research Jonathan Knowles characterized THP's platform as adding 'cutting-edge capabilities' and an 'excellent strategic fit' with Roche's…
Patent Docs covers the THP and BioVeris acquisitions back-to-back, highlighting Roche's parallel expansion into both polyclonal antibody platforms and…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$56.5M cash. Transgenic rabbit human polyclonal antibody platform. Source: BioWorld, Fierce Biotech, PharmaTimes.
Roche paid $56.5M for a human-antibody platform in 2007 and the founders left to build a rival that became far more valuable elsewhere.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Therapeutic Human Polyclonals Inc. (this deal) | 2007 | $56M | 23 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2007 deals · Roche Holding AG deals